Renault appoints Josep Maria Recasens chief strategy officer-February 2024-www.financetom.com

Renault appoints Josep Maria Recasens chief strategy officer

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Renault appoints Josep Maria Recasens chief strategy officer

Nov 16, 2025 11:57 PM

Nov 17 (Reuters) - French automaker Renault

has appointed Josep Maria Recasens chief strategy officer,

replacing Guido Haak, it said on Monday.

The chief executive of the group's Iberian peninsula and

electric division Ampere will take the role effective

immediately, Renault said in a statement.

(Reporting by Nathan Vifflin in Gdansk; Editing by Emelia

Sithole-Matarise)

Previous page： Next page： Fox Insider Sold Shares Worth $1,027,800, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Jun 10, 2024

...

Fox Insider Sold Shares Worth $1,027,800, According to a Recent SEC Filing

Jun 10, 2024

03:29 AM EDT, 06/10/2024 (MT Newswires) -- Steven Tomsic, Chief Financial Officer, on June 07, 2024, sold 30,000 shares in Fox (FOX) for $1,027,800. Following the Form 4 filing with the SEC, Tomsic has control over a total of 110,568 shares of the company, with 110,568 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1754301/000162828024027349/xslF345X03/wk-form4_1717798026.xml ...

T-Mobile US Insider Sold Shares Worth $1,809,800, According to a Recent SEC Filing

Jun 10, 2024

03:30 AM EDT, 06/10/2024 (MT Newswires) -- Peter Osvaldik, Executive Vice President and Chief Financial Officer, on June 05, 2024, sold 10,000 shares in T-Mobile US ( TMUS ) for $1,809,800. Following the Form 4 filing with the SEC, Osvaldik has control over a total of 81,307 shares of the company, with 81,307 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1283699/000128369924000076/xslF345X03/wk-form4_1717798045.xml Price:...

Biogen, Eisai Say Alzheimer's Maintenance Treatment Application Accepted by US FDA

Jun 10, 2024

03:43 AM EDT, 06/10/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said Sunday the US Food and Drug Administration has accepted a supplemental biologics license application for monthly intravenous maintenance dosing of Leqembi for the treatment of early Alzheimer's disease. Under the proposed treatment plan, patients who have completed the biweekly intravenous initiation phase would receive a monthly dose to...